th-65jx900w th-65jx7的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列免費下載的地點或者是各式教學

共同負載綠茶茶枝萃取物和β-胡蘿蔔素的水包油包水型雙重乳化液之製備及特性分析

為了解決th-65jx900w th-65jx7的問題，作者林芷柔 這樣論述：

綠茶 (Camellia sinensis) 茶枝為食品加工過程中的副產品，其含有能帶來健康益處的兒茶素。β-胡蘿蔔素則是一種天然的著色劑，且具有高的抗氧化活性。然而，兒茶素和β-胡蘿蔔素皆對環境敏感，因此生物利用率低。故本研究目的為探討以水包油包水型雙重乳化液共包覆綠茶茶枝萃取物和β-胡蘿蔔素之製備及特性。首先將茶枝以蒸餾水分別於70、80和90℃萃取20分鐘，接著測定萃取物中的生物活性，然後萃取物進一步製備成乳化液，並分析其穩定性。結果顯示，萃取物的產率隨著溫度 (70-90℃) 上升而增加，其中以90℃萃取的組別有著最高的產率 (17.50 ± 0.33%)。80℃萃取物的總多酚和總類

黃酮分別為162.88 ± 1.58 µg沒食子當量/mg和236.33 ± 0.28 µg檞皮素當量/mg，皆較70℃和90℃萃取物高。此外80℃萃取物的DPPH (EC50=17.51 ± 0.15 µg/mL) 和ABTS+ (EC50=71.66 ± 1.10 µg/mL) 自由基清除活性，也輕微較70℃和90℃萃取物佳。除此之外，三種萃取物皆具有良好的α-葡萄糖苷酶抑制活性。乳化液結果顯示，以80% Span 80和20% Tween 20穩定的乳化液在儲存期間具有最高的乳化液穩定指數 (100.00 ± 0.00 - 92.98 ± 2.76%)。以葡萄糖作為賦形劑比起抗壞血酸更能

維持乳化液的穩定性，也能具有較好的膠囊化效率。雙重乳化液的粒徑會隨著儲存時間或儲藏溫度增加而變大，表面電位則會下降，這些都可能降低乳化液的整體穩定性。乳化液的L*、a*和b*值皆會隨儲存時間增加而降低，在高溫時下降越快。綜上所述，以80℃水萃取綠茶茶枝可獲得較豐富的抗氧化物質，將其與β-胡蘿蔔素共同包覆製備成的雙重乳化液具有可以開發成機能性食品的潛力。

水飛薊奈米載體對胃繞道術後和肥胖動物的吸收與治療影響

為了解決th-65jx900w th-65jx7的問題，作者陳君漢 這樣論述：

指導教授推薦書...................................................口試委員會審定書.................................................誌謝............................................................iii中文摘要.........................................................iv英文摘要....................................................

......v第一章 導論 .....................................................1第一節 肥胖與減重手術.............................................1第二節 非酒精性脂肪肝炎...........................................2第三節 胃繞道手術............................................... 3第四節 水飛薊素.................................................

4第五節 奈米藥物載體............................................. 5第六節 非酒精性脂肪肝炎治療..................................... 5第二章 實驗目的................................................ 7第一節 胃繞道術後的奈米化水飛薊素藥物動力學.............................................................. 7第二節 奈米化水飛薊素對肥胖及非酒精性肝炎的治療................

...7第三章 實驗一 胃繞道術後的奈米化水飛薊素藥物動力學............... 9第一節 材料方法................................................. 9第二節 結果..................................................... 15第三節 討論..................................................... 21第四節 表(一) ~ (三)............................................ 29第五節 圖(一)

~ (五)............................................ 30第四章 實驗二 奈米化水飛薊素對肥胖及非酒精性肝炎的治療.......... 38第一節 實驗方法................................................. 38第二節 結果..................................................... 43第三節 討論..................................................... 49第四節 表(四) ~ (五)........

.................................... 57第五節 圖(六) ~ (十二).......................................... 58第五章 結論.................................................... 67參考文獻........................................................ 69List of FiguresFigure 1. Transmission electron microscopic (TEM) photographs

of SNEDDS-F1 at the magnifications of (A) x75000 and (B) x200000.... 30Figure 2. Roux-en-Y gastric bypass (RYGB) in the rat model: (A) an intraoperative imaging of RYGB rat; (B) the view of GI tract exposed outside the abdominal cavity; and (C) the change of body weight of sham rats and RYGB rats a

fter operation.......................... 31Figure 3. Pharmacokinetic profiles of silibinin after oral administration of aqueous suspension, PEG400 solution, and SNEDDS-F1: (A) mean plasma concentration of silibinin versus time curves in normal rats; (B) mean plasma concentration of silibinin versus

time curves in RYGB rats; and (C) The comparison of area under curve (AUC) of the plasma concentration-time curves........................................................ 32-33Figure 4. The fluorescence imaging of stomach and intestine of rats after oral administration of Nile red-containing PEG400

solution and SNEDDS-F1: (A) the macroscopic observation of GI tract exposed outside the abdominal cavity after oral administration of PEG400 and SNEDDS-F1 in RYGB rats; (B) the microscopic observation of stomach (x 100) after oral administration of PEG400 and SNEDDS-F1 in normal rats; (C) the micros

copic observation of intestine (x 100) after oral administration of PEG400 and SNEDDS-F1 in normal rats; (D) the microscopic observation of stomach (x 100) after oral administration of PEG400 and SNEDDS-F1 in RYGB rats; (E) the microscopic observation of intestine (x 100) after oral administration o

f PEG400 and SNEDDS-F1 in RYGB rats; (F) confocal imaging of stomach (x 100) after oral administration of PEG400 and SNEDDS-F1 in RYGB rats; (G) confocal imaging of intestine (x 100) after oral administration of PEG400 and SNEDDS-F1 in RYGB rats.......................................................

...... 34Figure 5. The histopathological observation of stomach and intestine of rats after oral administration of Nile red-containing PEG400 solution and SNEDDS-F1: (A) H&E staining of stomach (x 40) after oral administration of PEG400 and SNEDDS-F1 in normal rats; (B) H&E staining of intestine (x

100) after oral administration of PEG400 andSNEDDS-F1 in normal rats; (C) COX-2 staining of stomach (x 40) after oral administration of PEG400 and SNEDDS-F1 in normal rats; (B) COX-2 staining of intestine (x 100) after oral administration of PEG400 and SNEDDS-F1 in normal rats.......................

............... 36-37Figure 6. The experimental protocols of nanomedicine admistration and RYGB for histological examination (A) and pharmacokinetic evaluation (B).............................................................. 58Figure 7. The physicochemical characterization of lipid nanoparticles: T

he morphology of SNEDDS-F2 and NLC viewed by TEM (A) and the polarity of SNEDDS-F2 and NLC determined by the solvatochromism of Nile red (B)........................................................... 59-60Figure 8. Roux-en-Y gastric bypass (RYGB) in the obese rat model: The change of body weight of

HFF rats administered with silibinin in aqueous suspension and lipid nanocarriers (A), schematic diagram of the RYGB procedure (B), intraperative photograph showing the creation of BP and RL (C), and the change of body weight of HFF rats after RYGB and sham operation.................................

........... 61-62Figure 9. The histopathological observation of rat liver after oral administration of silibinin in aqueous suspension and lipid nanocarriers and RYGB: appearance of the liver (A), H&E staining (B), Masson’s trichrome staining (C), and oil red O staining (D)..........................

.................................... 63Figure 10. The semiquantitative histology scoring of liver: the distribution of NAFLD and NASH according to SAF score (A) and the staging of fibrosis (B).......................................... 64Figure 11. The bioimages from the obese rats at 4 h following o

ral administration of iFluor® 790 in aqueous suspension and lipid nanocarriers: the representative peripheral organ images (A), the microscopic observation of stomach (B), and the microscopic observation of intestine (C).............................................................. 65Figure 12. Phar

macokinetic profiles of silibinin after oral administration of aqueous suspension and lipid nanocarriers: mean plasma concentration of silibinin versus time curves in obese rats without RYGB (A) and mean plasma concentration of silibinin versus time curves in obese rats with RYGB (B)................

.............................................. 66List of TablesTable 1. The characterization of self-nanoemulsifying drug delivery systems formulation 1 (SNEDDS-F1) in double-distilled water and simulated gastric fluid (SGF) by mean diameter and zeta potential, and particle numbers..................

........................................ 29Table 2. Pharmacokinetic parameters of silibinin (144 mg/kg) after oral administration of silymarin from suspension, PEG400 solution, and self-nanoemulsifying drug delivery systems formulation 1(SNEDDS-F1) in control rats....................................

......................... 29Table 3. Pharmacokinetic parameters of silibinin (144 mg/kg) after oral administration of silymarin from suspension, PEG400 solution, and self-nanoemulsifying drug delivery systems formulation 1(SNEDDS-F1) in Roux-en-Y gastric bypass (RYGB) rats...........................

.................................. 29Table 4. The characterization of the self-nanoemulsifying drug delivery system formulation 2 (SNEDDS-F2) by mean diameter (nm), polydispersity index (PDI), and zeta potential....................57Table 5. Pharmacokinetic parameters of silibinin (300 mg/kg) after

oral administration of silybinin in SNEDDS-F2 and NLC in high fat fed (HFF) rats with or without RYGB............................................................. 57